6th Jul 2006 09:10
Sinclair Pharma PLC06 July 2006 SINCLAIR PHARMACEUTICALS APPOINTMENTS VP CORPORATE DEVELOPMENT AND CREATES OPERATING COMPANY FINANCE DIRECTOR London, 6 July 2006: Sinclair Pharma plc ("Sinclair" or the "Company") (SPH.L),the specialty pharmaceutical company focused on the acquisition and developmentof patented pharmaceutical products, today announces the appointment of DaniloCasadei Massari as Vice President of Corporate Development and the promotion ofAlan Olby to the new role of Finance Director of Sinclair Pharmaceuticals Ltd.,Sinclair Pharma plc's operating company, both with immediate effect. In his role as Vice President Corporate Development at Sinclair, Mr Massari willjoin the Board of Sinclair's operating company, Sinclair Pharmaceuticals Ltd.He will be responsible for the group's operating pharmaceutical sales andmarketing companies and for the international expansion of Sinclair's own salesand marketing capability. Mr Massari has over thirty years of senior commercial management experience inthe pharmaceutical industry and joins Sinclair from Madaus Group where he wasmost recently VP, Corporate Development and CEO of Madaus SrL, Italy. Mr.Massari established Madaus's operations in Italy and in his group corporatedevelopment role was responsible for coordinating all aspects of businessdevelopment in the business's subsidiaries in Portugal, Spain, France, Italy,Germany, Austria and Belgium. Prior to Madaus, Mr Massari has held a number of executive pharmaceuticalindustry roles; these include the founding in 1991 of Istoria Farmaceutici SrL,Italy and Expharma SrL and their subsequent sale in 1997 to ShirePharmaceuticals and Stallergenes respectively. Until 1991 he was at FidiaFarmaceutici SpA, an Italian based multinational specialty pharma, with businessoutlets in over 18 countries. He was latterly their Director of InternationalCorporate Development coordinating all international teams with a special focuson major EEC Countries, North America and Far East. He also spent four years atFidia as President and CEO of Fidia Pharmaceutical Corporation, Washington D.C.,USA and established its US subsidiary. Dr Michael Flynn, CEO of Sinclair commented: "I am very pleased to welcome Danilo Massari aboard at this important time inthe Company's development as we continue grow our own sales presence in keymarkets. Our objectives are to cover the major healthcare markets, to improvemargins and maintain control of our brands. Danilo joins us with an excellenttrack record of success and brings a new range of expertise and experience tothe company which will substantially increase the strength of our managementteam." Alan Olby joins the Board of Sinclair's operating company, SinclairPharmaceuticals Ltd, as Finance Director. In this role he will join theExecutive Management Board of the Group. He joined Sinclair from Xenova Groupwhere he was Group Financial Controller. Commenting, Sinclair's Chief Financial Officer Jerry Randall said: "I am delighted to announce Alan Olby's promotion to Finance Director ofSinclair Pharmaceuticals Limited. As the Group grows, this promotion will allowme to focus more of my time directly on Group matters. Since Alan has joinedSinclair he has made a tremendous contribution to the Group and this promotionrecognises Alan's achievements and invaluable contribution so far." For more information please contact: Sinclair PharmaceuticalsDr Michael Flynn, CEOTel: +44 (0) 1483 426 644John Barrington-Carver (Media Enquiries)Tel: +44 (0) 7831 655 630 Financial DynamicsBen Atwell / John GilbertTel +44 (0) 207 831 3113 Notes to Editors Sinclair Pharma plc: Sinclair Pharma plc based in Godalming in the UK, is quoted on the AlternativeInvestment Market (AIM) (SPH.L) on the London Stock Exchange and has focused onthe acquisition and development of niche patented pharmaceutical products in thefields of oral health and dermatology, and bringing them to the internationalmarket place via out-licensing partners. The Company combines product evaluation, product development, regulatory andbusiness development expertise to add value to its acquired and in-housedeveloped products. A key element of the Sinclair business model is to minimiserisk and exposure by avoiding involvement in lengthy R&D programmes and rapidlyachieving global distribution through a network of marketing partners. TheCompany has already licensed its products for distribution in over 60 countriesaround the world. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma